Lung resistance-related protein (LRP) is a human major vault protein (MVP) implicated in drug resistance of cancer cells in a cell-type dependent manner. The primary goal of the study was to understand the role(s) of LRP in doxorubicin (DOX) resistance of non-small cell lung cancer (NSCLC) cells and the underlying working mechanisms. In the study, the roles of LRP in the regulation of DOX dynamics, nuclear import of minor vault proteins (vault poly (ADP-ribose) polymerase, vPARP and telomerase associated protein-1, TEP-1) and DOX-mediated cytotoxicity were examined in CH27 and H460 cells. Our results were the first to show that the CH27 cells with higher LRP expression levels were more resistant to DOX-induced cytotoxicity as shown in apoptosis experiments. LRP at the nuclear membrane could regulate DOX efflux from the nucleus to the cytosol, and also the reverse vPARP/TEP1 influx from the cytosol, to protect NSCLC cells from DOX-induced apoptosis. Cytosolic LRP could bind to DOX, vPARP and TEP1 to clear DOX away from the nucleus and promote the assembly of vaults for cell protection again. Based on the data obtained, the molecular mechanisms responsible for DOX resistance of NSCLC were delineated to demonstrate that LRP, vPARP and TEP1 were potential targets for NSCLC therapy. Inhibitors of these proteins, including small interfering LRP (siLRP), wheat-germ agglutenin (WGA), 3-aminobenzamide (3-AB) and 3,6,9-trisubstituted acridine 9-[4-(N,N-dimethylamino) phenylamino]-3,6-bis(3-pyrrolodinopropionamido) acridine (BRACO-19), break down the DOX resistance of NSCLC cells, particularly in CH27 cells, and may have therapeutic values in the control of NSCLC.
Introduction
Multidrug resistance (MDR) developed in nonsmall cell lung cancer (NSCLC), which constitutes 85% of lung cancers, has been a major issue in NSCLC therapy (15, 17) . We have recently reported that CH27 cells, derived from a human lung squamous carcinoma, have higher resistance to doxorubicin (DOX)-induced cytotoxicity compared to H460 cells, which were derived from a large-cell lung carcinoma. The underlying mechanism(s) responsible for DOX resistance of CH27 cells, however, remained still unclear.
DOX, used in combination with other therapeutic drugs, has been used to treat various cancers including breast, prostate and lung cancers (2, 29, 46) . DOX belongs to the anthracycline family and can easily enter the nucleus to intercalate with DNA (9) , disrupt topoisomerase II function (34) , inhibit DNA synthesis and gene transcription and lead to cell death (20, 33) . Therapeutic value of DOX in cancer therapy has been limited due to its side effects on heart tissues (20, 36) , and the emergence of drug resistance of treated cancer cells (41, 45) .
Lung resistance-related protein (LRP) has been suggested to play a role in MDR of cancer cells (5, 24, 31) , and is viewed as a prognostic marker in cancer therapy (28, 35) . In lung cancers, NSCLC tissues often express higher levels of LRP than in SCLC tissues (11) ; over-expression of LRP has also been found in primary NSCLC cells, especially in well-differentiated squamous cell carcinomas (32) . LRP expression can even be up-regulated in lung cancer cells by sub-lethal dose of anti-cancer drugs (3, 13, 50) . LRP-mediated DOX resistance of NSCLC cells, particularly in squamous carcinomas, is therefore anticipated, and the underlying mechanism(s) is worthy of elucidation.
LRP was first identified in a lung cancer cell line with MDR and so was named (40) . It was later reported as a drug resistance-related major vault protein (MVP) in human (39) . Vaults are large, ovoid ribonucleoprotein particles that were first discovered in 1986 (21) and are composed of MVP such as human LRP, which constitutes more than 70% of the vaults, minor vault proteins, vault poly (ADP-ribose) polymerase (vPARP) and telomerase associated protein-1 (TEP1), and a small untranslated vault RNA (vRNA) (23, 26) . Approximately 5% of the vaults is localized at the nuclear membrane, nuclear pore complex (NPC) or nucleoplasm of the nucleus (7, 44, 48) , but the majority of the vaults has a cytoplasmic localization and association with vesicular structures (21, 31, 40) . Intracellular distribution of LRP from cytoplasm to nucleus is also known to be microtubule-dependent (48) . Based on its nuclear distribution and association with NPC, vault/LRP has been suggested to also participate in NPC-mediated nucleo-cytoplasmic exchange (7, 8, 37, 38) . NPC is a multicomponent structure that allows a bidirectional nucleo-cytoplasmic exchange of molecules, particles and drugs (39) . Contradictory results disproving the nucleo-cytoplasmic transporting role of LRP, however, have also been reported (48) . The barrel shape of the vault complex and its association with cytoplasmic vesicles have given Vault/LRP, at cytoplasmic compartment, a potential role in the sequestration of drugs into exocytotic vesicles (10, 18, 21) . The functions of vPARP and TEP1 in the vault and drug resistance are presently unclear. Their siblings, PARP and TEP, residing outside the vault complexes, are, however, known to participate in DNA repair, apoptosis inhibition and telomerase protection (16, 19) . Whether vPARP and TEP1 of vaults act the same by moving into the nucleus to protect cell from DNA damage remains to be investigated.
In this work, the putative roles of LRP in regulating the nucleo-cytoplasmic transport of DOX, vPARP and TEP1 and the DOX-mediated cytotoxicity have been examined in NSCLC in the DOX-resistant CH27 and DOX-susceptible H460 cells. Possible therapeutic values of LRP, vPARP and TEP1 inhibitors in breaking down DOX resistance of NSCLC cells were also evaluated. The molecular mechanism(s) involved in DOX resistance of NSCLC were also further delineated.
Materials and Methods

Reagents and Antibodies
DOX, 3-aminobenzamide (3-AB; vPARP inhibitor), BRACO-19 (B-19; TEP1 inhibitor), cycloheximide (CHX) and wheat germ agglutinin (WGA; inhibitor of nuclear transport) were purchased from Sigma Aldrich (St. Louis, MO, USA); cosmic calf serum from HyClone (South Logan, UT, USA); enhanced chemiluminescent (ECL) substrate kit from Perkin Elmer (Waltham, MA, USA); anti-LRP serum (610512) from BD (San Jose, CA, USA); anti-vPARP (NBP1-06563) and anti-TEP1 sera (NBP1-77285) from Novus (Littleton, CO, USA); anti-tubulin sera (05-829) from Millipore (Billerica, MA, USA); anti-TBP sera (sc-33736) from Santa Cruz (Dallas, TX, USA); small interfering RNA (siRNA) specific for LRP from OriGene (Rockville, MD, USA); TdT-mediated digoxigenin-dUTPnick-end labeling (TUNEL) assay kit from Biovision (Milpitas, CA, USA); Lipofectamine 2000 reagent from Gibco (Waltham, MA, USA).
Cell Culture
Human NSCLC cell lines, CH27 and H460, were kindly provided by Dr. Shih-Lan Hsu at Taichung Veterans General Hospital, Taichung, Taiwan. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% cosmic calf serum and pen-strep 1 at 37°C in a 5% CO 2 incubator.
siRNA Transfection CH27 and H460 cells were transiently transfected with 30 nM siRNA specific for LRP (siLRP group) or 30 nM non-specific siRNA (mock group) for 24 h, using Lipofectamine 2000 following the manufacturer's instructions. siRNA duplex sequences specific for LRP are:
rCrGrArCrUrArCrCrGrArGrArGrArArGrCrGrArGrCrCrCGC (SR306698B; from OriGene)
Drug Treatments
Prior to drug treatment, CH27 and H460 cells, with or without LRP knockdown, were pre-seeded onto 6-well (2 × 10 5 cells/well), 12-well (5 × 10 4 cells/well), 24-well (5 × 10 4 /well) or 96-well plates (3 × 10   3 cells/well), or 10-cm petri-dishes (5 × 10 5 cells/dish) for 24 h to allow cell attachment. The cells were then treated with DOX at various concentrations and for various times as specified in the absence or presence of various inhibitors as indicated. The inhibitors applied included CHX (50 μM) (48), WGA (40 μg/ml; a functional inhibitor of NPC), 3-AB (1 mM; a vPARP inhibitor) and B-19 (10 μM; a TEP1 inhibitor). At the end of drug treatment, cells were harvested and for further tests as indicated.
Trypan Blue Exclusion Assay
The viabilities of drug-treated cells were determined by trypan blue exclusion assay as previously described (47) . The number of the viable cells per well in each group was averaged from at least 3 replicate wells. Each experiment was carried out three times or more.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Assay
The viabilities of drug-treated cells were also determined by MTT assay as previously described (14) . Absorbance of each sample was measured at 570 nm and 630 nm on a microplate reader. Percent of group viability (over drug-free control group) was averaged from 6 repeats per group. Each experiment was carried out three times.
TUNEL Assay
DOX-induced DNA fragmentation in the absence or presence of siRNA of LRP, WGA, 3-AB or B-19 was determined by the TUNEL assay using the Apo-BrdU In Situ DNA fragmentation assay kit, according to the manufacturer's instructions (Biovision). Under a fluorescence microscope, the number of the apoptotic cells (in green) in each group was counted and averaged from 15 randomly picked visual fields out of 3 coverslips (wells) per group. Each experiment was performed three times or more.
Flowcytometry to Determine the Nucleo-Cytoplasmic (N/C) Ratio of DOX
The impact of LRP upon the N/C exchange of DOX was determined by flowcytometry and the derived N/C ratio of DOX. Briefly, treated cells (by DOX, siLRP, CHX or WGA) in 6-well plates were harvested for flowcytometry analysis of the percent of DOXpositive cells over 10,000 cells in each group, using a FACScan flow cytometer (Becton Dickinson) as previously described (14) . In another set of experiments, treated cells from each group were harvested and lysed by 0.1% Triton X-100 at 10 min to collect nuclei (14) for flowcytometry analysis. The red fluorescence emissions from DOX positive cells or nuclei were collected through a 575 nm band-pass filter, and were automatically plotted in a log mode using the Cellquest software. The N/C ratio of DOX was calculated based on the following equation: [percent of DOX-positive nuclei/percent of DOX-positive cells-percent of DOX (+) nuclei]. Each experiment was carried out three times or more.
Laser Scanning Confocal Microscopy (LSCM)
Compartmental distribution of DOX and LRP in DOX-treated cells was determined by LSCM as previously described (49) . Briefly, the treated cells on the coverslip in each well in a 24-well plate were fixed with 4% paraformaldehyde for 10 min, stained with 4',6-diamidino-2-phenylindole (DAPI) (2 μg/ml, 1 h), followed by detection of DOX by LSCM. To trace the intracellular distribution of LRP, paraformaldehydefixed cells were labeled with mouse monoclonal antibodies specific for LRP (BD; 610512) for 3 h, the secondary antibody (fluorescein isothiocyanate (FITC)-congugated goat anti-mouse IgG) for 1 h, and then stained with DAPI for 1 h at room temperature. Cells were subjected to LSCM for tracing of LRP (FITCpositive) and nuclei (DAPI-positive) under a fluorescence confocal microscope (Axio Imager.A1, Carl Zeiss; Jena, Germany). The excitation/emission wavelengths employed were 488/510 nm for FITC, 488/ 570 nm for DOX and 488/488 nm for DAPI. Each experiment was carried out 3 times or more.
Protein Preparations
Total, cytosolic and nuclear proteins were extracted from the drug-treated cells as previously described (27, 49) . Protein extracts prepared were aliquoted and stored at -80°C until needed. The protein concentrations were estimated with the Bradford method (4).
Co-Immunoprecipitation (Co-IP) Assay
Binding of LRP with vPARP or TEP1 was determined by Co-IP assays (27) . Briefly, cytosolic proteins extracted from DOX-treated cells in 10 cm dish plates were immunoprecipitated with monoclonal antibodies specific for LRP or IgG control antibodies as described (42) . Equal aliquots of the LRP immunoprecipitates, pulled down by protein G agarose beads, from each group were then subjected to Western blot analysis in three or more experiments.
LRP-DOX Binding Assay
Binding of LRP with DOX was determined using similar procedures as described above, except that equal aliquots of the LRP immunoprecipitates from each group were subjected to the Western blot analysis for LRP expression and the fluorescence measurement of DOX using a Enzyme-linked immunosorbent assay (ELISA) reader at 570 nm. Each experiment was carried out at least three times.
Western Blot Analysis
The protein expression levels of total, cytosolic and nuclear LRP, vPARP and TEP1 were determined by Western blot analysis as previously described (27) . For immunoblotting, the primary antibodies applied in the study included mouse monoclonal anti-LRP (diluted 2,000-fold), mouse polyclonal anti-tubulin (diluted 10,000-fold), rabbit polyclonal anti-vPARP (diluted 2,000-fold), anti-TEP1 (diluted 2,000-fold) and anti-TBP sera by overnight incubation at 4°C. The secondary antibodies used were horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (diluted 10,000-fold) and HRP-conjugated goat anti-rabbit IgG (diluted 60,000-fold) sera by incubating for 1 h at room temperature. Blots were developed by ECL kit (Perkin Elmer). The protein expression levels of respective target proteins were averaged from three individual experiments. Values in histogram are mean ± standard deviation (SD) from three independent repeats.
Statistical Analysis
Analysis of variance (ANOVA) followed by a multiple comparison test (Fisher PLSD), with a value of 0.05, was used to determine the group differences in respective tests.
Results
CH27 Cells Shows Higher DOX Resistance than H460 Cells
Drug resistance of NSCLC was first compared between CH27 and H460 cells by treating cells with DOX at 1, 5, and 10 μM concentrations for 24 h, followed by cell viability measurement. Results from the trypan blue exclusion assay showed that the number of living CH27 and H460 cells were all significantly decreased by DOX in a dose-dependent manner. The number of living CH27 cells was significantly higher than that of H460 cells receiving the same dose of DOX, P < 0.05 (Fig. 1A) . Similar results were also seen in MTT assay (Fig. 1B) . IC 50 values of DOX for CH27 and H460 cells determined by MTT assay were 2.22 μM and 1.18 μM, respectively. The time response of both cell lines to DOX (1 μM) treatment was also determined by MTT assay, and the results showed that cell viability of both cell lines were inhibited by DOX in a timedependent manner. Viability of CH27 cells was signi- ficantly higher than that of H460 cells starting from 12 h after DOX treatment (Fig. 1C ). All the results indicated that CH27 cells were more resistant to DOX than H460 cells.
DOX Significantly Increases the Expression of LRP, TEP1 and vPARP in CH27 but not H460 Cells
To investigate whether DOX resistance of CH27 cells was LRP-dependent, the protein expression levels of three vault proteins LRP, vPARP and TEP1, and the compartmental distribution of LRP were determined by Western blotting and LSCM; and the data obtained were compared between CH27 and H460 cells in the absence or presence of 1 µM DOX for 0, 6, 12, 24 or 48 h. Results of Western blotting (Figs. 2A & 2B) showed that the expression levels of total and nuclear, but not cytosolic, LRP of CH27 cells were significantly increased by DOX at 6, 12, 24 and 48 h after drug treatment. The protein expression levels of total and nuclear LRP of H460 cells, on the other hand, were significantly inhibited by DOX starting from 6 h (nuclear LRP) or 12 h (total LRP) after drug treatment. The levels of cytosolic LRP of H460 cells were, however, not altered by DOX. DOX-induced LRP expressions of CH27 cells at total, cytosolic and nuclear level was all significantly higher than that of H460 cells at all the time points. The protein expression levels of total and nuclear, but not cytosolic, TEP1 of CH27 cells were also significantly increased by DOX at 24 and 48 h after drug treatment. The levels of TEP1 of H460 cells were significantly inhibited by DOX at 6, 12, and 24 h for total TEP1, 24 and 48 h for cytosolic TEP1 and 48 h for nuclear TEP1. The protein expression levels of total and nuclear, but not cytosolic, vPARP of CH27 cells were again significantly increased by DOX at 24 and 48 h after drug treatment. The levels of total, cytosolic and nuclear vPARP of H460 cells were not significantly altered by DOX except that total vPARP was significantly inhibited by DOX at 48 h. Total TEP1 (6-48 h), cytosolic TEP1 (12-48 h), nuclear TEP1 (12-48 h), total vPARP (12-48 h) and nuclear vPARP (6-48 h) of CH27 cells were all significantly higher than that of H460 cells at the indicated time periods. Results also showed that the nuclear fraction isolated from both cell lines contained only TBP but not tubulin whereas the cytosolic fractions contained only tubulin but not TBP (see Suppl. Fig. 1 ), proving that the nuclear fractions applied in the study were free of cytoplasmic contamination and vice versa. LSCM was further applied to trace the compartmental distribution of LRP in both cell lines. Data in Fig. 2C again showed that with or without 1µM DOX for 24 h, CH27 cells expressed higher levels of LRP (bright green spots were densely spread) than H460 cells (bright green spots were loosely spread). In both cell lines, LRPs mainly appeared at in the cytosol but few also appeared at the nuclear membrane region. Overall, DOX-treated CH27 cells appeared to have higher levels of LRP, TEP1 and vPARP than H460 cells. The protein expression levels of total and nuclear LRP, TEP1 and vPARP were significantly increased by DOX in CH27 but not H460 cells. Most of cytosolic vault proteins, except TEP1 of H460 cells, were not significantly altered by DOX probably due to ubiquitous distribution of vaults in the cytosol to see the DOX effects.
LRP Protects NSCLC Cells from DOX-Induced Apoptosis Likely by Promoting DOX Efflux from the Nucleus
LRP is known as a MVP. DOX-increased LRP and drug resistance were both observed in CH27 but not H460 cells. The role of LRP in the protection of CH27 cells from DOX-induced cytotoxicity was therefore further examined by siRNA knockdown. Briefly, both cell lines were transfected with siRNA specific for LRP (30 nM) for 24 h then followed by 1 μM DOX treatment for another 24 h. Western blot analysis showed that at the end of the DOX treatment, total, cytosolic and nuclear LRP were all significantly down regulated by siRNA in both cell lines, comparing with the DOX/siLRP and DOX/Mock group, P < 0.05 ( Fig. 3A and Suppl. Fig. 2) . Results from MTT assay showed that H460 and CH27 cell viabilities in the DOX/ siLRP groups were also significantly decreased compared to their DOX/Mock controls, but the viabilities of CH27 cells were still significantly higher than that of H460 cells receiving the same treatment (DOX/Mock or DOX/siLRP) (Fig. 3B) . TUNEL assay, however, showed that the degrees of apoptosis caused by DOX in both cell lines were all significantly increased in the DOX/siLRP groups compared to their DOX/Mock controls, and apoptosis of CH27 cells was significantly lower than that of H460 cells in the DOX/Mock and DOX/siLRP group, P < 0.05 (Fig. 3C) .
The impact of LRP upon DOX efflux from the nucleus to cytosol was further determined by flowcytometric analysis to acquire the N/C ratio of DOX. Higher DOX efflux from the nucleus can is expected to lead to lower N/C ratios of DOX. The results showed that the N/C ratios of DOX in DOX/siLRP-treated H460 and CH27 cells were all significantly increased compared to the respective DOX/Mock controls (Fig. 3D) . The increase of N/C ratio was about 19×[(673%-34%)/34%] in H460 cells and 7.5 × [(655%-77%)/ 77%] in CH27 cells, indicating that LRP was critical for promoting DOX efflux in both cell lines. To further support the role of LRP in the regulation of DOX efflux, LSCM was also performed (Fig. 3E) . Data showed that when LRP level of H460 and CH27 cells were knocked down by siLRP, the amount of DOX 
LRP Acts through NPC to Promote DOX Efflux to Protect Cells from DOX -Induced Apoptosis
LRP has been implicated in nucleo-cytoplasmic transport process due to its association with NPC but its involvement seems to be cell-type dependent (7, 8, 38, 48) . We, therefore, investigated if LRP acts similarly in NSCLC cells to promote DOX efflux from the nucleus to the cytosol to protect cells from DOXinduced apoptosis. Two chemical blockers, CHX and WGA were used in the study. CHX is a protein synthesis inhibitor that has been reported to transiently alter the NPC structure, widening it to trap vaults/LRPs at NPC (12, 48) . WGA is a lectin, which can bind to NPC and inhibit nucleo-cytoplasmic transport (1) of various substances, including LRP. When CH27 or H460 cells were co-treated with DOX (1 μM) and CHX (50 μM) for 24 h, the results showed that cytosolic LRP was significantly decreased whereas nuclear LRP increased on CHX treatment, compared to the DOX-only control ( Fig. 4A and Suppl. Fig. 3 ), indicating that CHX indeed can trap LRP in the nucleus. Although CHX did not significantly increase the survival rate of DOX-treated cells (Fig. 4B) , the N/C ratio of DOX was decreased by CHX (Table 1 and Suppl. Fig. 4 ), indicating that DOX efflux had been triggered. Results from LSCM analysis were in consistent with the above finding showing that less DOX but increased LRP (white arrows, Fig. 4C ) was found in the nucleus and the nuclear membrane of DOX/CHX-treated H460 and CH27 cells compared to the DOX control groups (Fig. 4C) . Results further showed that when H460 and CH27 cells were cotreated with 1 μM DOX and 40 μg/ml WGA for 24 h, total LRP was not altered, but cytosolic LRP increased and nuclear LRP decreased in the DOX/WGA-treated cells compared to the DOX control groups (Fig. 5A and Suppl. Fig. 5 ), demonstrating that nuclear importation of LRP could indeed be blocked by WGA. The N/C ratio of DOX was also greatly increased by WGA in both cell lines (Table 2 and Suppl. Fig.  6 ), indicating that more DOX was accumulated within the nucleus as a result of WGA treatment. Results from LSCM analysis clearly showed that more DOX indeed accumulated in the nucleus whereas more LRP was trapped in the cytosol (bright green spots with red arrows, Fig. 5B ) of DOX/CHX-treated H460 and CH27 cells compared to the DOX-only controls (Fig. 5B) . TUNEL assay further showed that DOX-induced apoptosis of the cells was significantly increased by WGA (Fig. 5C and Suppl. Fig.7 ). Cell viabilities of DOX-treated H460 and CH27 cells were, on the contrary, significantly decreased by WGA compared to the DOXonly control (Fig. 5D ). Taken together, the results supported the notion that nuclear LRP can could act through NPC to trigger DOX efflux from the nucleus to the cytosol, an event which that in turn protected NSCLC cells from DOX-induced apoptosis. The results also suggest that WGA may have therapeutic values in counteracting DOX resistance of NSCLCs.
Nuclear LRP Promotes Nuclear Import of vPARP and TEP1 to Protect NSCLC Cells from DOX-Induced Apoptosis
Since vault/LRP has been implicated in the nucleo-cytoplasmic bidirectional transport of various molecules, particles and drugs (39), we next investigated whether LRP in the nucleus also acts through NPC to promote the nuclear import of TEP1 and vPARP for cell protection. TEP1 and vPARP are two minor vault proteins but their functions in vaults are still unclear. Outside the vaults, TEP and PARP could protect the genomic profile of the cell (25, 27) . Results showed that when nuclear LRP was knocked down by siLRP, the amounts of nuclear vPARP and TEP1 were also significantly decreased in both cell lines (DOX/ siLRP versus DOX/Mock group, P < 0.05) (Fig. 6A and Suppl. Fig. 8 ). When nuclear LRP was trapped in NPC (nucleus) of DOX-treated cells were further treated with CHX, the amounts of nuclear vPARP and TEP1 of CH27 cells were significantly increased, but only nuclear TEP1 was increased in H460 cells (Fig. 6B and Suppl. Fig. 9 ). On the other hand, when nuclear LRP was down-regulated by WGA, nuclear vPARP and TEP1 were also significantly decreased in both cell lines (Fig. 6C and Suppl. Fig. 10 ). The results suggested that NPC-associated LRP promoted the nuclear import of vPARP and TEP1. TUNEL and MTT assays further demonstrated that once vPARP and TEP1 were inhibited by 3-AB (vPARP inhibitor; 1 mM), or BRACO-19 (B-19, TEP1 inhibitor; 10 μM), DOX-induced apoptosis (Fig. 6D and Suppl. Fig. 11 ) and cytotoxicity ( Fig. 6E) were both further exacerbated in both cell lines compared to their DOX controls. Hence, nuclear LRP can also was demonstrated to promote the nuclear import of vPARP and TEP1 to protect NSCLCs from DOX-induced apoptosis. The anti-apoptotic role of vPARP and TEP1 shown in this work has not previously been reported.
Cytosolic LRP Retains DOX at the Cytosol and Promotes Vault Assembly
Since about 95% of vaults/LRPs is distributed in the cytosol (7, 31) , the role(s) of cytosolic LRP in regulating DOX resistance of NSCLC cells was next investigated. LRP has been implicated in the sequestration of drugs in exocytotic vesicles (10) . We, therefore, were interested to know if LRP could bind to DOX and retain it in the cytosol to prevent nuclear influx of DOX, resulting in cytotoxicity. We were also interested to know if LRP could bind to vPARP and TEP1 to promote the assembly of vaults. Data in Fig.7A showed that LRPs precipitated from 1 μM DOX-treated CH27 and H460 cells bound to DOX, and equal amounts of LRPs precipitated from DOX-treated (Fig. 7B , left panels). Proteins precipitated by non-specific antibodies from both cell lines showed no binding affinities to DOX, vPARP or TEP1 (Fig. 7B, right panels) . DOX treatment significantly increased the binding affinity of LRPs to vPARP and TEP1 in CH27 cells, but only to TEP1, not vPARP, in H460 cells (Fig. 7B, left panels) . The results indicated that LRP could bind to and retain DOX within the cytosol to prevent DOX-mediated apoptosis in the nucleus. LRP concurrently bound to vPARP and TEP1 to promote the assembly of vaults in the cytosol. Both events induced cell protection. LRPs of CH27 cells had higher affinities to DOX, vPARP and TEP1 that may, in part, explain the higher DOX resistance of CH27 cells. We believe our results were the first to reveal the fact that LRP could protect NSCLC cells in both the nucleus and the cytosol through different mechanisms.
Discussion
LRP, vPARP and TEP1 Are Potential Targets for Cancer Therapy of NSCLC
LRP has been shown to be over-expressed in various cancer cells, including A549 NSCLC cells (5, 24, 31, 40) . Although LRP has been implicated in MDR of different cancer cells (5, 24, 31) , its action remained controversial. Some studies showed that up-regulation of LRP alone was insufficient to confer MDR (43) . Furthermore, disruption of expression of the LRP gene did not induce hypersensitivity to cytostatics (30) , and LRP or TEP1 knockout mice did not develop cancers (22, 30) .
Our results showed for the first time that LRP, vPARP and TEP1 all played a critical role in DOX resistance of two NSCLC cell lines. CH27 cells with higher DOX resistance also had higher expression levels of these proteins, particularly in the nucleus. Specific blockade of LRP, vPARP and TEP1 by siRNAs or chemical inhibitors was effective in breaking down DOX resistance of both cell lines. The results suggested that LRP, vPARP and TEP1 were potential targets for NSCLC therapy; and blockers of these proteins may have therapeutic values in the control of NSCLC.
LRP-Mediated DOX Resistance in the Nucleus
The mechanisms underlying LRP-mediated DOX resistance have also been elucidated. The data showed that LRP protected NSCLC cells through different ways at both the nuclear and cytosolic levels. It is known that only a small amount (5%) of vault/LRP is found at the nuclear membrane zone, NPC or nucleoplasm in different cell types (7, 44, 48) . In DOX-treated CH27 or H460 cells, nuclear LRPs mainly distributed at the nuclear membrane zone and were NPC-associated based on the observations that structural alteration induced by CHX, or inhibition by WGA of NPC, could alter the nuclear level and functions of LRP. NPC-associated distribution of LRP has also been reported in another NSCLC cell line, SW1573 by van Zon et al. (44, 48) .
NPC-associated LRP has been demonstrated to play a critical role in regulating nuclear DOX efflux from and the influx of vPARP and TEP1 to the nucleus. Both events could protect NSCLC cells from DOXinduced apoptosis and contribute to the DOX resistance of the cells. Involvement of LRP in NPC-regulated bidirectional nucleo-cytoplasmic transport of intracellular substances has also been reported previously by other groups (7, 8, 37, 38) .
LRP-Mediated DOX Resistance at Cytosol
The role of cytosolic LRP in protecting NSCLC cells from DOX-induced cytotoxicity has also been investigated because 95% of the vault complexes are located at in the cytosol, and so are LRP, vPARP and TEP (7, 31) . Our results have provided the first evidence of a novel function of LRP not previously reported. In the cytosol, LRP could bind to DOX, vPARP and TEP1 to either prevent DOX from entering the nucleus, or promote the assembly of vaults. Both events again protected NSCLC cells from DOX-induced apoptosis and contributed to DOX resistance of the cells. The DOX binding affinity of LRP isolated from DOXtreated CH27 cells was significantly higher than that isolated from DOX-treated H460 cells, consistent with higher DOX resistance of CH27 cells compared to H460 cells.
LRP-Mediated DOX Resistance Is Cell Type-Dependent
Although DOX-induced up-regulated LRP expression has also been reported in other lung cancer cells (3, 13, 50) , DOX resistance of A549, derived from an adenocarcinoma of NSCLC, has been attributed to ABCG2 pump (G2 subtype of membrane transporter of ATP-binding cassette family) rather than LRP (45). Our study, however, showed that CH27 cells, derived from a squamous NSCLC, and H460, established from large cells of NSCLC, were both dependent on LRP to develop the DOX resistance, indicating that LRPmediated DOX resistance was cell type-dependent. In addition, our recent studies have demonstrated that ATP-binding cassette (ABC) transporters, p-glycoprotein and multidrug resistance-associated protein 1 also contribute to the high DOX resistance of CH27 cells by pumping DOX out of the cells (6) . The results collectively further suggest that CH27 cells acts through various molecular mechanisms, such as LRP, MRP1 or P-gp, to combat DOX-mediated cytotoxicity and to develop DOX resistance.
vPARP and TEP1-Mediated DOX Resistance: A Novel Anti-Apoptotic Role
Other than being the components of vault particles, the biological function(s) of vPARP and TEP1 have rarely been reported. Their siblings, PARP and TEP, outside the vaults are known to protect the genomic profile of the cell (16, 19) . Our results demonstrated for the first time that vPARP and TEP1 can both protected NSCLC cells from DOX-induced apoptosis and contributed to DOX resistance of the cells.
In summary, the novelty of this study was to uncover the molecular mechanisms involved in DOX resistance of NSCLC cells, and to reveal that LRP, vPARP and TEP1 are potential targets for cancer therapy of DOX-resistant NSCLCs. Therapeutic values of siLRP, WGA, 3-AB or B-19 in overcoming DOX resistance of NSCLCs may be considered for used in combination with DOX in NSCLC therapy. 
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